Merck Animal Health Reports Acquisition of Elanco Animal Health’s Aqua Business for ~$1.3B
Shots:
- Merck Animal Health has entered into a definitive agreement to acquire Elanco’s aqua business for strengthening its aqua portfolio by owning Clynav, a DNA-based vaccine for protecting Atlantic salmon against pancreas disease and Imvixa, for anti-parasitic sea lice treatment
- The acquisition, to be concluded by mid-2024, comes with a portfolio of products for warm water production, complementing its warm water vaccine portfolio and DNA-based vaccine technology to develop novel vaccines for the aqua industry
- Furthermore, the deal includes a portfolio of medicines, vaccines, nutritional and supplements for aquatic species, two related aqua manufacturing facilities in Canada & Vietnam along with a research facility in Chile
Ref: Merck Animal Health | Image: Merck Animal Health
Related News:- Elanco Reports the First Shipment of Varenzin-CA1 for Anemia associated with CKD in Felines within the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
